Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Blood blood.2024026401.

https://doi.org/10.1182/blood.2024026401

Published: 2025

Includes: Supplemental data

Journal Articles

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Yujun Dai, Xue-Ping Li, Yang Liang

Blood (2024) 144 (Supplement 1): 192.

https://doi.org/10.1182/blood-2024-200714

Published: 2024

Journal Articles

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li, Jian Ge, Shiguang Ye, Lili Zhou, Yiming Gong, Huaying Ruan, Hosein Kouros-Mehr, Aibin Liang

Blood (2024) 144 (Supplement 1): 3475.

https://doi.org/10.1182/blood-2024-199236

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

Haichen Wei, Lijie Xing, Dan Liu, Hui Wang, Ping Li, Zengjun Li

Blood (2024) 144 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2024-204844

Published: 2024

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2023-189475

Published: 2023

Journal Articles

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Bin Xue, Xiu Luo, Yifan Liu, Lili Zhou, Shiguang Ye, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2023-184885

Published: 2023

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

Journal Articles

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Bin Xue, Xiu Luo, Yifan Liu, Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2023-180500

Published: 2023

Journal Articles

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Shiguang Ye, Lili Zhou, Yan Lu, Xiu Luo, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2023-184765

Published: 2023

Journal Articles

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Yan Lu, Shiguang Ye, Lili Zhou, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2023-182763

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Lili Zhou, Yifan Liu, Shiguang Ye, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3137.

https://doi.org/10.1182/blood-2023-184352

Published: 2023

Journal Articles

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Lili Zhou, Shiguang Ye, Xiuyong Dang, Shaoguang Li, Ping Li

Blood (2023) 142 (Supplement 1): 6276.

https://doi.org/10.1182/blood-2023-186563

Published: 2023

NARROW

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only